Page 1 | Search Results | Blood Advances | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Race and ethnicity reporting and representation in hemophilia clinical trials

Stacey A. Fedewa, Leonard A. Valentino, Andee Koo, Lorraine Cafuir, Duc Q. Tran, Ana Antun, Christine L. Kempton

Blood Adv (2024) 8 (10): 2351–2360.

https://doi.org/10.1182/bloodadvances.2024012862

Published: 2024

Journal Articles

Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A

Christine L. Kempton, Stacey A. Fedewa

Blood Adv (2024) 8 (5): 1190–1199.

https://doi.org/10.1182/bloodadvances.2023011974

Published: 2024

Includes: Supplemental data

Journal Articles

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz-Priel, Guy Young, Víctor Jiménez-Yuste

Blood Adv (2022) 6 (24): 6140–6150.

https://doi.org/10.1182/bloodadvances.2022007458

Published: 2022

Includes: Supplemental data

Journal Articles

Inhibitors and mortality in persons with nonsevere hemophilia A in the United States

Ming Y. Lim, Dunlei Cheng, Michael Recht, Christine L. Kempton, Nigel S. Key

Blood Adv (2020) 4 (19): 4739–4747.

https://doi.org/10.1182/bloodadvances.2020002626

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice

M. Neale Weitzmann, Susanne Roser-Page, Tatyana Vikulina, Daiana Weiss, Li Hao, W. Hunter Baldwin, Kanglun Yu, Natalia del Mazo Arbona, Meghan E. McGee-Lawrence, Shannon L. Meeks, Christine L. Kempton

Blood Adv (2019) 3 (3): 288–300.

https://doi.org/10.1182/bloodadvances.2018027557

Published: 2019

Includes: Supplemental data

Journal Articles

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Christine L. Kempton, Amanda B. Payne

Blood Adv (2018) 2 (14): 1750–1755.

https://doi.org/10.1182/bloodadvances.2018019323

Published: 2018

NARROW

Race and ethnicity reporting and representation in hemophilia clinical trials

Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Inhibitors and mortality in persons with nonsevere hemophilia A in the United States

Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Email alerts

ASH Publications

American Society of Hematology

Race and ethnicity reporting and representation in hemophilia clinical trials

Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Inhibitors and mortality in persons with nonsevere hemophilia A in the United States

Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only